Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) Net Income towards Common Stockholders: 2023-2025

Historic Net Income towards Common Stockholders for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to -$35.3 million.

  • Inhibrx Biosciences' Net Income towards Common Stockholders rose 19.62% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 109.44%. This contributed to the annual value of $1.7 billion for FY2024, which is 803.96% up from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Net Income towards Common Stockholders is -$35.3 million, which was down 23.04% from -$28.7 million recorded in Q2 2025.
  • Over the past 5 years, Inhibrx Biosciences' Net Income towards Common Stockholders peaked at $1.9 billion during Q2 2024, and registered a low of -$92.0 million during Q4 2023.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$45.9 million (2024), whereas its average is $138.8 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 3,898.37% in 2024, then crashed by 101.54% in 2025.
  • Quarterly analysis of 3 years shows Inhibrx Biosciences' Net Income towards Common Stockholders stood at -$92.0 million in 2023, then skyrocketed by 47.96% to -$47.9 million in 2024, then climbed by 19.62% to -$35.3 million in 2025.
  • Its Net Income towards Common Stockholders was -$35.3 million in Q3 2025, compared to -$28.7 million in Q2 2025 and -$43.3 million in Q1 2025.